Martoni Moura e Silva
Date of Birth: Sept 29, 1977
Infectious disease specialist since 2009.
Bachelor’s at Medicina from Universidade Federal da Bahia (2002).
Work in Acre-Amazonic region, specially with Hepatitis B,C and Delta and Hepatic Elastography.
Preceptor ID specialist in Hospital das Clinicas do Acre until 2017. Currently work at Public Viral Hepatits Center in Santa Catarina – south of Brazil.
Hepatitis C is considered an important chronic disease due to its silent evolution and complications such as liver cirrhosis and hepatocarcinoma, which are prominent causes of liver transplantation. In Brazil, hepatitis C treatment is indicated according to the degree of hepatic fibrosis in most cases. The goal of this study was to assess hepatic fibrosis by means of non-invasive methods (elastography, APRI and FIB-4) in hepatitis C carriers treated with direct-acting antivirals (DAA’s). METHODS: This is an intervention pre-experimental study in which carriers of hepatitis C virus (HCV) started antiviral treatment between October 2015 and September 2017 in Rio Branco-Acre, Brazil. RESULTS: 95 patients were included in the study, most of them were males (84.2%) aging from 51 to 60 years (46.3%), having reported an elementary level of education in approximately 60% of the cases. Genotype 1 (73.7%) was the most frequent HCV genotype, followed by genotypes 3 (24.2%) and 2 (2.1%). All parameters evaluated through liver elastography and APRI and FIB-4 scores demonstrated an improvement in liver cirrhosis degree after treatment with DAA’s. CONCLUSIONS: HCV treatment with direct-acting antivirals, regardless of liver cirrhosis existence or previous treatment with pegylated interferon and ribavirin, contributed to significant reduction in kPa index and METAVIR score as assessed by liver elastography, and yet in APRI and FIB-4 scores.